NervGen Pharma Corp. Common stock (NGEN) Stock Analysis & Investment Frameworks

NervGen Pharma Corp. Common stock (NGEN) stock analysis on Invetso. Review NervGen Pharma Corp. Common stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

NervGen Pharma Corp. Common stock Company Overview

NervGen Pharma Corp. Common stock Key Financial Metrics

About NervGen Pharma Corp. Common stock

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

NervGen Pharma Corp. Common stock Investment Frameworks

Invetso analyzes NervGen Pharma Corp. Common stock (NGEN) across the following frameworks:

Explore More NGEN Research